S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
He's Giving Away His Ultimate Dividend Package FOR FREE! (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Day of Financial Reckoning Is Near (Ad)
NASDAQ:MRKR

Marker Therapeutics - MRKR Competitors

$0.40
+0.01 (+2.57%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.39
$0.40
50-Day Range
$0.26
$0.56
52-Week Range
$0.25
$2.05
Volume
384,887 shs
Average Volume
1.08 million shs
Market Capitalization
$33.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.25

MRKR vs. ORGS, IMV, CMMB, COCP, CRVS, CYCN, NLTX, TRVN, ASLN, and ACST

Should you be buying Marker Therapeutics stock or one of its competitors? The main competitors of Marker Therapeutics include Orgenesis (ORGS), IMV (IMV), Chemomab Therapeutics (CMMB), Cocrystal Pharma (COCP), Corvus Pharmaceuticals (CRVS), Cyclerion Therapeutics (CYCN), Neoleukin Therapeutics (NLTX), Trevena (TRVN), ASLAN Pharmaceuticals (ASLN), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.

Marker Therapeutics vs.

Orgenesis (NASDAQ:ORGS) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

Orgenesis has higher revenue and earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$35.50 million1.31-$18.05 million$0.1711.00
Marker Therapeutics$1.24 million26.93-$41.88 million-$0.50-0.80

Orgenesis has a net margin of 11.76% compared to Marker Therapeutics' net margin of 0.00%. Orgenesis' return on equity of 9.02% beat Marker Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Orgenesis 11.76% 9.02% 5.85%
Marker Therapeutics N/A -97.35% -62.97%

15.2% of Orgenesis shares are held by institutional investors. Comparatively, 31.8% of Marker Therapeutics shares are held by institutional investors. 7.7% of Orgenesis shares are held by insiders. Comparatively, 27.2% of Marker Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Marker Therapeutics received 70 more outperform votes than Orgenesis when rated by MarketBeat users.

CompanyUnderperformOutperform
OrgenesisN/AN/A
Marker TherapeuticsOutperform Votes
70
63.06%
Underperform Votes
41
36.94%

Orgenesis has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

In the previous week, Marker Therapeutics had 3 more articles in the media than Orgenesis. MarketBeat recorded 7 mentions for Marker Therapeutics and 4 mentions for Orgenesis. Orgenesis' average media sentiment score of 1.88 beat Marker Therapeutics' score of 1.32 indicating that Orgenesis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orgenesis
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Marker Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Marker Therapeutics has a consensus price target of $1.25, suggesting a potential upside of 212.97%. Given Marker Therapeutics' higher possible upside, analysts plainly believe Marker Therapeutics is more favorable than Orgenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Marker Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Orgenesis beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRKR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MRKR vs. The Competition

MetricMarker TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$33.39M$5.63B$4.39B$6.38B
Dividend YieldN/A2.41%7.34%3.17%
P/E Ratio-0.8010.70123.3818.51
Price / Sales26.93468.132,940.91128.88
Price / CashN/A21.8222.6729.84
Price / Book0.758.656.436.21
Net Income-$41.88M$187.51M$166.90M$239.70M
7 Day Performance-22.07%5.67%4.68%4.54%
1 Month Performance19.58%11.47%10.78%12.20%
1 Year Performance-77.31%-31.64%-26.68%-20.33%

Marker Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORGS
Orgenesis
0 of 5 stars
$1.66
flat
N/A-63.8%$41.20M$35.50M9.77111News Coverage
High Trading Volume
IMV
IMV
1.8725 of 5 stars
$0.50
+2.0%
$2.75
+447.3%
-58.9%$41.34M$190,000.00-0.9997Analyst Revision
CMMB
Chemomab Therapeutics
2.0984 of 5 stars
$3.63
+3.7%
$25.00
+588.7%
-73.5%$41.40MN/A-2.5920Gap Up
COCP
Cocrystal Pharma
2.2722 of 5 stars
$0.42
+4.9%
$4.50
+959.1%
-53.4%$41.42M$2.01M-2.6613News Coverage
Positive News
Gap Up
CRVS
Corvus Pharmaceuticals
2.4186 of 5 stars
$0.86
-1.1%
$6.00
+596.5%
-43.2%$40.11MN/A-0.9628
CYCN
Cyclerion Therapeutics
2.3062 of 5 stars
$0.96
+1.1%
$10.50
+993.8%
-71.9%$41.71M$3.94M-0.7732Short Interest ↓
Gap Up
NLTX
Neoleukin Therapeutics
2.4876 of 5 stars
$0.98
+1.0%
$12.67
+1,188.2%
-82.7%$41.79MN/A-0.8991Positive News
Gap Up
TRVN
Trevena
2.0413 of 5 stars
$0.24
+14.3%
$4.75
+1,879.2%
-80.8%$39.76M$570,000.00-0.6925Analyst Report
Gap Down
ASLN
ASLAN Pharmaceuticals
2.0084 of 5 stars
$0.60
+9.1%
$5.50
+816.7%
-68.0%$41.85M$3M-1.0918Analyst Report
Positive News
Gap Up
ACST
Acasti Pharma
2.3818 of 5 stars
$0.89
+3.5%
$6.00
+575.7%
-73.6%$39.51M$200,000.00-4.9332Short Interest ↓
Positive News
This page (NASDAQ:MRKR) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.